資源描述：
《Platinum-based chemotherapy in triple-negative breast cancer. a systematic review and meta-analysis of randomized-controlled trials》由會員上傳分享，免費在線閱讀，更多相關內(nèi)容在學術論文-天天文庫。
1、Clinicalreport1Platinum-basedchemotherapyintriple-negativebreastcancer:asystematicreviewandmeta-analysisofrandomized-controlledtrialsXiuwenGuan,FeiMa,YingFan,WenjieZhu,RuoxiHongandBingheXuTheaimofthisstudywastoevaluatethebenefitsofthebothinthefixed-effectsmodel(RR=1.43,P<0.0
2、001)andadditionofplatinumagentsforthetreatmentofpatientsintherandom-effectsmodel(RR=1.47,P=0.01).Thewithtriple-negativebreastcanceronthebasisofresultsseemedtoyieldabetterresponserateandrandomized-controlledtrials(RCTs).Afullyrecursivepathologicalcompleteresponserateforplatin
3、um-basedliteraturesearchwasperformedintheCochraneControlledtherapyintriple-negativebreastcancer.However,becauseTrialsRegisterDatabases,Medline,EMBASE,andChineseoftheheterogeneousnatureofprimarytrialoutcomes,BiomedicalLiteratureDatabaseinanylanguage.RCTswerecautionshouldbeexe
4、rcisedincomingtothisconclusionconsideredforinclusion.Eightrandomized-controlledtrialsandfurtherresearchisnecessarytosupportthesetotaling1142patientswereincluded.Theobjectivefindings.Anti-CancerDrugs00:000–000Copyright?2015responseratewasreportedinsixRCTs,whichweredividedWolt
5、ersKluwerHealth,Inc.Allrightsreserved.intotwosubgroups:palliativechemotherapyforaAnti-CancerDrugs2015,00:000–000metastaticsettingandneoadjuvantchemotherapy.Usingthefixed-effectsmodel,thedifferencebetweentheKeywords:breastcancer,meta-analysis,platinum,triple-negativeplatinum-
6、basedgroupandthenon-platinum-basedgroupDepartmentofMedicalOncology,CancerHospital,ChineseAcademyofMedicalwasfoundtobestatisticallysignificantintheoverallstudySciencesandPekingUnionMedicalCollege,Beijing,China[relativerisk(RR)=1.36,P<0.00001],thesubgroupofCorrespondencetoFeiM
7、a,MD,DepartmentofMedicalOncology,Cancerpalliativechemotherapy(RR=2.42,P<0.00001),andtheHospital,ChineseAcademyofMedicalSciencesandPekingUnionMedicalCollege,No.17,PanjiayuanNanli,ChaoyangDistrict,Beijing100021,Chinasubgroupofneoadjuvant(RR=1.15,P=0.01).PathologicalTel:+861087
8、788114;fax:+861087715711;e-mail:drmafei@126.comcompleteresponserateswerebas
